{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:38:04Z","timestamp":1793140684692,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04963-w","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:52:43Z","timestamp":1778478763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum ferritin, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio are associated with levodopa-induced dyskinesia severity in Parkinson\u2019s disease"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0457-9972","authenticated-orcid":false,"given":"Farrukh","family":"Saidvaliyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9384-7716","authenticated-orcid":false,"given":"Dilyora","family":"Pulatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3219-5539","authenticated-orcid":false,"given":"Ibodulla","family":"Kilichev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9675-5419","authenticated-orcid":false,"given":"Adkham","family":"Yusupov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8557-040X","authenticated-orcid":false,"given":"Gulnora","family":"Shamuratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4519-5636","authenticated-orcid":false,"given":"Xusan","family":"Turdibekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5013-4936","authenticated-orcid":false,"given":"Mukhriddin","family":"Pulatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1601-1838","authenticated-orcid":false,"given":"Jasur","family":"Saidov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9080-1011","authenticated-orcid":false,"given":"Nozimakhon","family":"Mirhayotova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2220-0345","authenticated-orcid":false,"given":"Yulduz","family":"Axmedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7408-7068","authenticated-orcid":false,"given":"Dilnoza","family":"Abdullayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"7","key":"4963_CR1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/mdc3.14056","volume":"11","author":"D Santos-Garc\u00eda","year":"2024","unstructured":"Santos-Garc\u00eda D, De Deus T, Cores C, et al. Levodopa\u2010Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson\u2019s Disease: A 5\u2010Year Follow\u2010Up Study. Mov Disord Clin Pract. 2024;11(7):830\u201349. https:\/\/doi.org\/10.1002\/mdc3.14056.","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"4963_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00441-018-2813-2","volume":"373","author":"H You","year":"2018","unstructured":"You H, Mariani LL, Mangone G, Le Nailly F, Charbonnier-Beaupel D, Corvol F. Molecular basis of dopamine replacement therapy and its side effects in Parkinson\u2019s disease. Cell Tissue Res. 2018;373(1):111\u201335. https:\/\/doi.org\/10.1007\/s00441-018-2813-2.","journal-title":"Cell Tissue Res"},{"issue":"3","key":"4963_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u201358. https:\/\/doi.org\/10.1002\/mds.1090.","journal-title":"Mov Disord"},{"issue":"13","key":"4963_CR4","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.3390\/jcm12134427","volume":"12","author":"L Di Biase","year":"2023","unstructured":"Di Biase L, Pecoraro PM, Carbone SP, Di Caminiti ML. Levodopa-Induced Dyskinesias in Parkinson\u2019s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions. JCM. 2023;12(13):4427. https:\/\/doi.org\/10.3390\/jcm12134427.","journal-title":"JCM"},{"issue":"11","key":"4963_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657\u201373. https:\/\/doi.org\/10.1038\/s41577-022-00684-6.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4963_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/mds.28075","volume":"36","author":"EC Hirsch","year":"2021","unstructured":"Hirsch EC, Standaert DG. Ten Unsolved Questions About Neuroinflammation in Parkinson\u2019s Disease. Mov Disord. 2021;36(1):16\u201324. https:\/\/doi.org\/10.1002\/mds.28075.","journal-title":"Mov Disord"},{"issue":"4","key":"4963_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/mds.27947","volume":"35","author":"S Genoud","year":"2020","unstructured":"Genoud S, Senior AM, Hare DJ, Double KL. Meta-Analysis of Copper and Iron in Parkinson\u2019s Disease Brain and Biofluids. Mov Disord. 2020;35(4):662\u201371. https:\/\/doi.org\/10.1002\/mds.27947.","journal-title":"Mov Disord"},{"key":"4963_CR8","doi-asserted-by":"publisher","first-page":"647168","DOI":"10.3389\/fnins.2021.647168","volume":"15","author":"T Song","year":"2021","unstructured":"Song T, Li J, Mei S, et al. Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease. Front Neurosci. 2021;15:647168. https:\/\/doi.org\/10.3389\/fnins.2021.647168.","journal-title":"Front Neurosci"},{"key":"4963_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fneur.2019.00384","volume":"10","author":"X Qiu","year":"2019","unstructured":"Qiu X, Xiao Y, Wu J, Gan L, Huang Y, Wang J. C-Reactive Protein and Risk of Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis. Front Neurol. 2019;10:384. https:\/\/doi.org\/10.3389\/fneur.2019.00384.","journal-title":"Front Neurol"},{"issue":"30","key":"4963_CR10","doi-asserted-by":"publisher","first-page":"eaat4579","DOI":"10.1126\/sciimmunol.aat4579","volume":"3","author":"K Ley","year":"2018","unstructured":"Ley K, Hoffman HM, Kubes P, et al. Neutrophils: New insights and open questions. Sci Immunol. 2018;3(30):eaat4579. https:\/\/doi.org\/10.1126\/sciimmunol.aat4579.","journal-title":"Sci Immunol"},{"key":"4963_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","volume":"60","author":"A Varatharaj","year":"2017","unstructured":"Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017;60:1\u201312. https:\/\/doi.org\/10.1016\/j.bbi.2016.03.010.","journal-title":"Brain Behav Immun"},{"issue":"1","key":"4963_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00018-024-05402-0","volume":"81","author":"X Sun","year":"2024","unstructured":"Sun X, Gu R, Bai J. Differentiation and regulation of CD4\u2009+\u2009T cell subsets in Parkinson\u2019s disease. Cell Mol Life Sci. 2024;81(1):352. https:\/\/doi.org\/10.1007\/s00018-024-05402-0.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"4963_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cell.2019.08.053","volume":"179","author":"M Prinz","year":"2019","unstructured":"Prinz M, Jung S, Priller J. Microglia Biology: One Century of Evolving Concepts. Cell. 2019;179(2):292\u2013311. https:\/\/doi.org\/10.1016\/j.cell.2019.08.053.","journal-title":"Cell"},{"key":"4963_CR14","doi-asserted-by":"publisher","first-page":"1322228","DOI":"10.3389\/fneur.2024.1322228","volume":"15","author":"F Li","year":"2024","unstructured":"Li F, Weng G, Zhou H, et al. The neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-high-density-lipoprotein ratio are correlated with the severity of Parkinson\u2019s disease. Front Neurol. 2024;15:1322228. https:\/\/doi.org\/10.3389\/fneur.2024.1322228.","journal-title":"Front Neurol"},{"key":"4963_CR15","doi-asserted-by":"publisher","first-page":"105480","DOI":"10.1016\/j.parkreldis.2023.105480","volume":"112","author":"P Grillo","year":"2023","unstructured":"Grillo P, Sancesario GM, Bovenzi R, et al. Neutrophil-to-lymphocyte ratio and lymphocyte count reflect alterations in central neurodegeneration-associated proteins and clinical severity in Parkinson Disease patients. Parkinsonism Relat Disord. 2023;112:105480. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105480.","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"4963_CR16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov Disord"},{"issue":"16","key":"4963_CR17","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.22341","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile. Mov Disord. 2008;23(16):2398\u2013403. https:\/\/doi.org\/10.1002\/mds.22341.","journal-title":"Mov Disord"},{"issue":"15","key":"4963_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS\u2010UPDRS): Scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"issue":"5","key":"4963_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.25383","volume":"28","author":"GT Stebbins","year":"2013","unstructured":"Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson\u2019s disease rating scale: Comparison with the unified Parkinson\u2019s disease rating scale. Mov Disord. 2013;28(5):668\u201370. https:\/\/doi.org\/10.1002\/mds.25383.","journal-title":"Mov Disord"},{"issue":"15","key":"4963_CR20","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 2010;25(15):2649\u201353. https:\/\/doi.org\/10.1002\/mds.23429.","journal-title":"Mov Disord"},{"issue":"12","key":"4963_CR21","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805\u201312. https:\/\/doi.org\/10.1172\/JCI200318921.","journal-title":"J Clin Invest"},{"issue":"10","key":"4963_CR22","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","volume":"13","author":"RJ Ward","year":"2014","unstructured":"Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045\u201360. https:\/\/doi.org\/10.1016\/S1474-4422(14)70117-6.","journal-title":"Lancet Neurol"},{"issue":"3","key":"4963_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/ejn.14290","volume":"49","author":"MG Tansey","year":"2019","unstructured":"Tansey MG, Romero-Ramos M. Immune system responses in Parkinson\u2019s disease: Early and dynamic. Eur J Neurosci. 2019;49(3):364\u201383. https:\/\/doi.org\/10.1111\/ejn.14290.","journal-title":"Eur J Neurosci"},{"issue":"10","key":"4963_CR24","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1002\/mds.28685","volume":"36","author":"L Mu\u00f1oz-Delgado","year":"2021","unstructured":"Mu\u00f1oz-Delgado L, Mac\u00edas\u2010Garc\u00eda D, Jes\u00fas S, et al. Peripheral Immune Profile and Neutrophil\u2010to\u2010Lymphocyte Ratio in Parkinson\u2019s Disease. Mov Disord. 2021;36(10):2426\u201330. https:\/\/doi.org\/10.1002\/mds.28685.","journal-title":"Mov Disord"},{"issue":"2","key":"4963_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5603\/PJNNS.a2022.0014","volume":"56","author":"N Madetko","year":"2022","unstructured":"Madetko N, Migda B, Alster P, Turski P, Koziorowski D, Friedman A. Platelet-to-lymphocyte ratio and neutrophil-tolymphocyte ratio may reflect differences in PD and MSA-P neuroinflammation patterns. Neurol Neurochir Pol. 2022;56(2):148\u201355. https:\/\/doi.org\/10.5603\/PJNNS.a2022.0014.","journal-title":"Neurol Neurochir Pol"},{"issue":"12","key":"4963_CR26","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00702-012-0905-9","volume":"119","author":"H Mochizuki","year":"2012","unstructured":"Mochizuki H, Yasuda T. Iron accumulation in Parkinson\u2019s disease. J Neural Transm. 2012;119(12):1511\u20134. https:\/\/doi.org\/10.1007\/s00702-012-0905-9.","journal-title":"J Neural Transm"},{"issue":"S1","key":"4963_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/jnc.13425","volume":"139","author":"AA Belaidi","year":"2016","unstructured":"Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer\u2019s disease and Parkinson\u2019s disease: targets for therapeutics. J Neurochem. 2016;139(S1):179\u201397. https:\/\/doi.org\/10.1111\/jnc.13425.","journal-title":"J Neurochem"},{"issue":"11","key":"4963_CR28","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1002\/hbm.22928","volume":"36","author":"N He","year":"2015","unstructured":"He N, Ling H, Ding B, et al. Region-specific disturbed iron distribution in early idiopathic P arkinson\u2019s disease measured by quantitative susceptibility mapping. Hum Brain Mapp. 2015;36(11):4407\u201320. https:\/\/doi.org\/10.1002\/hbm.22928.","journal-title":"Hum Brain Mapp"},{"issue":"4","key":"4963_CR29","doi-asserted-by":"publisher","first-page":"e3489","DOI":"10.1002\/nbm.3489","volume":"30","author":"X Guan","year":"2017","unstructured":"Guan X, Xuan M, Gu Q, et al. Regionally progressive accumulation of iron in Parkinson\u2019s disease as measured by quantitative susceptibility mapping. NMR Biomed. 2017;30(4):e3489. https:\/\/doi.org\/10.1002\/nbm.3489.","journal-title":"NMR Biomed"},{"key":"4963_CR30","doi-asserted-by":"publisher","first-page":"1287917","DOI":"10.3389\/fnagi.2023.1287917","volume":"15","author":"S Hartono","year":"2023","unstructured":"Hartono S, Chen RC, Welton T, et al. Quantitative iron\u2013neuromelanin MRI associates with motor severity in Parkinson\u2019s disease and matches radiological disease classification. Front Aging Neurosci. 2023;15:1287917. https:\/\/doi.org\/10.3389\/fnagi.2023.1287917.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"4963_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/jnnp-2019-322042","volume":"91","author":"GEC Thomas","year":"2020","unstructured":"Thomas GEC, Leyland LA, Schrag AE, Lees AJ, Acosta-Cabronero J, Weil RS. Brain iron deposition is linked with cognitive severity in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2020;91(4):418\u201325. https:\/\/doi.org\/10.1136\/jnnp-2019-322042.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"4963_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxx031","volume":"29","author":"KF Kernan","year":"2017","unstructured":"Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401\u20139. https:\/\/doi.org\/10.1093\/intimm\/dxx031.","journal-title":"Int Immunol"},{"issue":"6","key":"4963_CR33","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1007\/s12035-020-02277-7","volume":"58","author":"N Zhang","year":"2021","unstructured":"Zhang N, Yu X, Xie J, Xu H. New Insights into the Role of Ferritin in Iron Homeostasis and Neurodegenerative Diseases. Mol Neurobiol. 2021;58(6):2812\u201323. https:\/\/doi.org\/10.1007\/s12035-020-02277-7.","journal-title":"Mol Neurobiol"},{"key":"4963_CR34","doi-asserted-by":"publisher","first-page":"1216905","DOI":"10.3389\/fnagi.2023.1216905","volume":"15","author":"Z Chen ting","year":"2023","unstructured":"Chen ting Z, Pan zhui C, Ruan lin X, et al. Evaluation of ferritin and TfR level in plasma neural-derived exosomes as potential markers of Parkinson\u2019s disease. Front Aging Neurosci. 2023;15:1216905. https:\/\/doi.org\/10.3389\/fnagi.2023.1216905.","journal-title":"Front Aging Neurosci"},{"key":"4963_CR35","doi-asserted-by":"publisher","unstructured":"Williams GP, Schonhoff AM, Sette A, Lindestam Arlehamn CS. Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson\u2019s Disease. Bloem BR, Brundin P, Tan EK, Harms A, Lindestam Arlehamn C, Williams-Gray C, eds. JPD. 2022;12(s1):S129-S136. https:\/\/doi.org\/10.3233\/JPD-223241.","DOI":"10.3233\/JPD-223241"},{"issue":"11","key":"4963_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657\u201373. https:\/\/doi.org\/10.1038\/s41577-022-00684-6.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"4963_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/ejn.14290","volume":"49","author":"MG Tansey","year":"2019","unstructured":"Tansey MG, Romero-Ramos M. Immune system responses in Parkinson\u2019s disease: Early and dynamic. Eur J Neurosci. 2019;49(3):364\u201383. https:\/\/doi.org\/10.1111\/ejn.14290.","journal-title":"Eur J Neurosci"},{"issue":"11","key":"4963_CR38","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"XY Qin","year":"2016","unstructured":"Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. JAMA Neurol. 2016;73(11):1316. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2742.","journal-title":"JAMA Neurol"},{"issue":"1","key":"4963_CR39","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1186\/1742-2094-9-188","volume":"9","author":"V Pisani","year":"2012","unstructured":"Pisani V, Stefani A, Pierantozzi M, et al. Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson\u2019s disease. J Neuroinflammation. 2012;9(1):670. https:\/\/doi.org\/10.1186\/1742-2094-9-188.","journal-title":"J Neuroinflammation"},{"key":"4963_CR40","doi-asserted-by":"publisher","first-page":"1322228","DOI":"10.3389\/fneur.2024.1322228","volume":"15","author":"F Li","year":"2024","unstructured":"Li F, Weng G, Zhou H, et al. The neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-high-density-lipoprotein ratio are correlated with the severity of Parkinson\u2019s disease. Front Neurol. 2024;15:1322228. https:\/\/doi.org\/10.3389\/fneur.2024.1322228.","journal-title":"Front Neurol"},{"key":"4963_CR41","doi-asserted-by":"publisher","first-page":"116638","DOI":"10.1016\/j.jns.2019.116638","volume":"409","author":"T Umehara","year":"2020","unstructured":"Umehara T, Oka H, Nakahara A, Matsuno H, Murakami H. Differential leukocyte count is associated with clinical phenotype in Parkinson\u2019s disease. J Neurol Sci. 2020;409:116638. https:\/\/doi.org\/10.1016\/j.jns.2019.116638.","journal-title":"J Neurol Sci"},{"issue":"3","key":"4963_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nri3399","volume":"13","author":"E Kolaczkowska","year":"2013","unstructured":"Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159\u201375. https:\/\/doi.org\/10.1038\/nri3399.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4963_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4049\/jimmunol.1200409","volume":"189","author":"C Allen","year":"2012","unstructured":"Allen C, Thornton P, Denes A, et al. Neutrophil Cerebrovascular Transmigration Triggers Rapid Neurotoxicity through Release of Proteases Associated with Decondensed DNA. J Immunol. 2012;189(1):381\u201392. https:\/\/doi.org\/10.4049\/jimmunol.1200409.","journal-title":"J Immunol"},{"key":"4963_CR44","doi-asserted-by":"publisher","first-page":"805388","DOI":"10.3389\/fphar.2022.805388","volume":"13","author":"R Bandopadhyay","year":"2022","unstructured":"Bandopadhyay R, Mishra N, Rana R, et al. Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease: A Perspective Through Preclinical and Clinical Evidence. Front Pharmacol. 2022;13:805388. https:\/\/doi.org\/10.3389\/fphar.2022.805388.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4963_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tins.2007.03.001","volume":"30","author":"P Calabresi","year":"2007","unstructured":"Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007;30(5):211\u20139. https:\/\/doi.org\/10.1016\/j.tins.2007.03.001.","journal-title":"Trends Neurosci"},{"issue":"10","key":"4963_CR46","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1002\/mds.28685","volume":"36","author":"L Mu\u00f1oz-Delgado","year":"2021","unstructured":"Mu\u00f1oz-Delgado L, Mac\u00edas\u2010Garc\u00eda D, Jes\u00fas S, et al. Peripheral Immune Profile and Neutrophil\u2010to\u2010Lymphocyte Ratio in Parkinson\u2019s Disease. Mov Disord. 2021;36(10):2426\u201330. https:\/\/doi.org\/10.1002\/mds.28685.","journal-title":"Mov Disord"},{"issue":"6","key":"4963_CR47","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/ana.25614","volume":"86","author":"S Yazdani","year":"2019","unstructured":"Yazdani S, Mariosa D, Hammar N, et al. Peripheral immune biomarkers and neurodegenerative diseases: A prospective cohort study with 20 years of follow-up. Ann Neurol. 2019;86(6):913\u201326. https:\/\/doi.org\/10.1002\/ana.25614.","journal-title":"Ann Neurol"},{"key":"4963_CR48","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fimmu.2019.00303","volume":"10","author":"F Garretti","year":"2019","unstructured":"Garretti F, Agalliu D, Lindestam Arlehamn CS, Sette A, Sulzer D. Autoimmunity in Parkinson\u2019s Disease: The Role of \u03b1-Synuclein-Specific T Cells. Front Immunol. 2019;10:303. https:\/\/doi.org\/10.3389\/fimmu.2019.00303.","journal-title":"Front Immunol"},{"issue":"1","key":"4963_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s40478-020-01083-5","volume":"8","author":"A Kouli","year":"2020","unstructured":"Kouli A, Camacho M, Allinson K, Williams-Gray CH. Neuroinflammation and protein pathology in Parkinson\u2019s disease dementia. acta neuropathol commun. 2020;8(1):211. https:\/\/doi.org\/10.1186\/s40478-020-01083-5.","journal-title":"acta neuropathol commun"},{"issue":"1","key":"4963_CR50","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12883-024-03887-7","volume":"24","author":"H Yi","year":"2024","unstructured":"Yi H, Liang X, Xu F, et al. Association between neutrophil-to-lymphocyte ratio and motor subtypes in idiopathic Parkinson\u2019s disease: a prospective observational study. BMC Neurol. 2024;24(1):379. https:\/\/doi.org\/10.1186\/s12883-024-03887-7.","journal-title":"BMC Neurol"},{"issue":"11","key":"4963_CR51","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.27815","volume":"34","author":"SK Nissen","year":"2019","unstructured":"Nissen SK, Shrivastava K, Schulte C, et al. Alterations in Blood Monocyte Functions in Parkinson\u2019s Disease. Mov Disord. 2019;34(11):1711\u201321. https:\/\/doi.org\/10.1002\/mds.27815.","journal-title":"Mov Disord"},{"key":"4963_CR52","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.expneurol.2017.11.010","volume":"300","author":"AS Harms","year":"2018","unstructured":"Harms AS, Thome AD, Yan Z, et al. Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Exp Neurol. 2018;300:179\u201387. https:\/\/doi.org\/10.1016\/j.expneurol.2017.11.010.","journal-title":"Exp Neurol"},{"issue":"33","key":"4963_CR53","doi-asserted-by":"publisher","first-page":"27806","DOI":"10.1074\/jbc.M112.388413","volume":"287","author":"E Santini","year":"2012","unstructured":"Santini E, Feyder M, Gangarossa G, Bateup HS, Greengard P, Fisone G. Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism. J Biol Chem. 2012;287(33):27806\u201312. https:\/\/doi.org\/10.1074\/jbc.M112.388413.","journal-title":"J Biol Chem"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04963-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04963-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04963-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:20:01Z","timestamp":1783038001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04963-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4963"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04963-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8934743\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted ethically in accordance with the guidelines of the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of Tashkent Medical Academy (approval No. TMA-IRB\/2020-12). Written informed consent was obtained from all participants prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"429"}}